86 studies found for:    coronado
Show Display Options
Rank Status Study
1 Not yet recruiting TSO for Plaque Psoriasis
Condition: Plaque Psoriasis
Intervention: Biological: Trichuris Suis Ova
2 Recruiting Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Condition: Acute Alcoholic Hepatitis
Interventions: Biological: ELAD  treatment;   Other: Standard of care (Control)
3 Active, not recruiting Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova (TSO);   Biological: Placebo
4 Active, not recruiting Trichuris Suis Ova in Autism Spectrum Disorders
Condition: Autism
Intervention: Drug: Trichuris Suis Ova
5 Completed
Has Results
Safety and Tolerability of Single Doses Oral CNDO 201 Trichuris Suis Ova in Patients With Crohn's Disease
Condition: Crohn's Disease
Interventions: Biological: Trichuris suis ova;   Other: Placebo
6 Recruiting Efficacy and Safety of Trichuris Suis Ova (TSO) as Compared to Placebo in Autism Spectrum Disorder
Condition: Autism
Interventions: Biological: Trichuris suis ova;   Other: Placebo
7 Recruiting CNDO-109-AANK for AML in First Complete Remission (CR1)
Condition: Acute Myeloid Leukemia
Intervention: Biological: CNDO-109-AANK Cells
8 Completed
Has Results
Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients
Condition: Hepatitis C Virus
Interventions: Drug: Sofosbuvir;   Drug: Placebo to match sofosbuvir;   Drug: PEG;   Drug: RBV
9 Completed GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection
Condition: Hepatitis C, Chronic
Interventions: Drug: GS-5885;   Drug: Tegobuvir;   Drug: GS-9451;   Drug: ribavirin tablet
10 Enrolling by invitation A Follow up Study Designed to Obtain Long Term Data on Subjects Who Either Achieved a Sustained Virologic Response or or Did Not Achieve a Sustained Virologic Response in an Abbott Sponsored Hepatitis C Study
Condition: Hepatitis C
Interventions: Drug: ABT-450/ritonavir;   Drug: ABT-333;   Drug: ABT-267
11 Completed Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)
Condition: Hepatitis C
Interventions: Drug: BI201335;   Drug: PegIFN/RBV
12 Active, not recruiting A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection
Condition: Hepatitis C Virus
Interventions: Drug: ABT-450/r;   Drug: ABT-267;   Drug: Ribavirin
13 Active, not recruiting Simtuzumab (GS-6624) in the Treatment of Liver Fibrosis in Subjects With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)
Condition: Non-Alcoholic Steatohepatitis (NASH)
Interventions: Biological: Simtuzumab 75 mg;   Biological: Simtuzumab 125 mg;   Biological: Placebo
14 Completed
Has Results
Phase 3 Study of Sofosbuvir and Ribavirin
Condition: Hepatitis C
Interventions: Drug: Sofosbuvir;   Drug: PEG;   Drug: RBV
15 Withdrawn A Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I
Condition: Chronic Hepatitis C Virus Genotype 1
Interventions: Drug: BMS-824393;   Drug: Placebo;   Drug: Peginterferon Alpha-2a;   Drug: Ribavirin
16 Completed
Has Results
Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects
Conditions: Hepatitis;   Hepatitis C
Interventions: Drug: Filibuvir;   Drug: Placebo
17 Completed
Has Results
Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6
Condition: Hepatitis C, Chronic
Interventions: Drug: Sofosbuvir;   Drug: RBV;   Drug: PEG
18 Recruiting The Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
Condition: Hepatic Encephalopathy
Interventions: Drug: Placebo;   Drug: Rifaximin
19 Completed
Has Results
Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon
Condition: Chronic Hepatitis C
Interventions: Drug: SOF;   Drug: RBV;   Drug: Placebo to match SOF;   Drug: Placebo to match RBV
20 Active, not recruiting A Study of Ritonavir-Boosted Danoprevir and RO5024048 in Different Combinations in Null Responder or Treatment-Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis
Condition: Hepatitis C, Chronic
Interventions: Drug: danoprevir;   Drug: ritonavir;   Drug: RO5024048;   Drug: peginterferon alfa-2a [Pegasys];   Drug: ribavirin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years